|Articles|March 21, 2023
Strategies for De-risking Early-Phase Oral Small Molecule Drug Development
Author(s)Catalent
Developers anxious to move their small molecule to Phase I may not have the time or resources to fully characterize the druggability of their candidate. Issues that could delay or even derail the program may appear in later clinical studies. Catalent has the resources to characterize lead molecules and develop the best pathway to bring them to Phase I studies and beyond.
Related Content
Trending on Pharmaceutical Technology
1
European Regulators Prepare the Pharma Industry for Future Changes as Legislation is Formalized
2
Assessment of Silicone Oil Cleaning on Indirect Surfaces in Aseptic Manufacturing
3
Shilpa CDMO to Launch as Dedicated Complex Small-Molecule Contract Development and Manufacturing Brand at CPHI Milan
4
Technology Transfer: Success Drivers and Obstacles Explained
5